62 results
DEF 14A
IMCR
Immunocore Holdings plc
12 Apr 24
Definitive proxy
4:20pm
officers is entitled to receive amounts earned during his or her term of service, including unpaid salary, reimbursement of unreimbursed business … or reimbursement of reasonable legal and professional fees, untaken holiday and any payment for the settlement of potential claims against the Group
424B7
IMCR
Immunocore Holdings plc
5 Apr 24
Prospectus with selling stockholder info
4:34pm
distribution and marketing partners’ ability to obtain coverage and adequate reimbursement and pricing for our medicines from government and third-party payors … and our distribution and marketing partners’ ability to obtain coverage and adequate reimbursement and pricing for our medicines from government and third
PRE 14A
IMCR
Immunocore Holdings plc
2 Apr 24
Preliminary proxy
4:45pm
officers is entitled to receive amounts earned during his or her term of service, including unpaid salary, reimbursement of unreimbursed business …
The Committee reserves the right to make payments it considers reasonable under a settlement agreement, including payment or reimbursement of reasonable legal
S-3ASR
IMCR
Immunocore Holdings plc
20 Mar 24
Automatic shelf registration
8:51pm
and our distribution and marketing partners’ ability to obtain coverage and adequate reimbursement and pricing for our medicines from government … and charges of, and reimbursement of the applicable expenses incurred by, the depositary.
Books of Depositary
The depositary maintains ADS holder records
10-K
2023 FY
EX-10.12
IMCR
Immunocore Holdings plc
28 Feb 24
Annual report
7:33am
Reimbursement.
(a) General. The Company will reimburse Executive for reasonable business expenses in accordance with the Company’s standard expense … reimbursement policy, subject to any applicable payroll withholdings and deductions (if any).
(b) Travel. Executive shall be entitled to reimbursement
10-K
xk1yvxb
28 Feb 24
Annual report
7:33am
10-K
EX-97.1
71x mjjyh10z2d504
28 Feb 24
Annual report
7:33am
10-K
EX-10.14
vj09419
28 Feb 24
Annual report
7:33am
10-K
EX-10.13
m3c xnxm34nmk4rryis
28 Feb 24
Annual report
7:33am
6-K
EX-99.3
chkxzqgxmkzkqljtsw9e
7 Nov 23
Current report (foreign)
7:09am
6-K
EX-99.2
ddv6yo57rv fxytqhlxy
7 Nov 23
Current report (foreign)
7:09am
6-K
EX-99.3
t3p9t5obd
10 Aug 23
Current report (foreign)
8:28am
6-K
EX-99.4
rzdh6aka2w1ur3j
10 Aug 23
Current report (foreign)
8:28am
6-K
EX-99.2
3wbxm7bp0m6d3l
10 Aug 23
Current report (foreign)
8:28am
6-K
EX-99.2
n0wfvbfw sy
10 May 23
Current report (foreign)
7:27am
6-K
EX-99.2
tqlkiuw0
9 Nov 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:15am
6-K
EX-99.4
ibofka8 0xc
9 Nov 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:15am
6-K
EX-99.3
oj66qjt0
9 Nov 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:15am
424B7
mmzpzzw
30 Sep 22
Prospectus with selling stockholder info
4:15pm
424B5
9veh5v5a1kxr39nmgj
9 Sep 22
Prospectus supplement for primary offering
4:23pm